Physician profile
Sahibjot Saini
NPI 1043054976
$794.98
in general payments reported to CMS, 2019-2025
13 companies · $552 in 2025
The $552 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $243 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $118.17 | 2025 | |
| Tg Therapeutics, INC. | $106.83 | 2025 | |
| Eisai INC. | $105.63 | 2025 | |
| Kyowa Kirin, INC. | $104.32 | 2024 | Nourianz |
| Acadia Pharmaceuticals INC | $100.80 | 2024 | Nuplazid |
| Pfizer INC. | $89.33 | 2025 | |
| Genentech USA, INC. | $39.49 | 2025 | Evrysdi |
| Lundbeck LLC | $29.11 | 2025 | Vyepti |
| Biogen, INC. | $23.79 | 2025 | Vumerity, Tysabri |
| Ucb, INC. | $21.61 | 2025 | Kygevvi |
| Janssen Pharmaceuticals, INC | $19.87 | 2024 | Xarelto |
| Amgen INC. | $18.21 | 2024 | Repatha |
| Abbvie INC. | $17.82 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sahibjot Saini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.